tiprankstipranks
Vireo Growth (TSE:VREO)
:VREO

Vireo Growth (VREO) Price & Analysis

10 Followers

VREO Stock Chart & Stats

C$0.58
-C$0.06(-7.06%)
At close: 4:00 PM EST
C$0.58
-C$0.06(-7.06%)

Vireo Growth News

VREO FAQ

What was Vireo Growth’s price range in the past 12 months?
Vireo Growth lowest stock price was C$13.65 and its highest was C$32.40 in the past 12 months.
    What is Vireo Growth’s market cap?
    Vireo Growth’s market cap is C$25.72B.
      When is Vireo Growth’s upcoming earnings report date?
      Vireo Growth’s upcoming earnings report date is Aug 06, 2026 which is in 61 days.
        How were Vireo Growth’s earnings last quarter?
        Vireo Growth released its earnings results on May 12, 2026. The company reported -C$0.546 earnings per share for the quarter, missing the consensus estimate of C$0.209 by -C$0.755.
          Is Vireo Growth overvalued?
          According to Wall Street analysts Vireo Growth’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Vireo Growth pay dividends?
            Vireo Growth does not currently pay dividends.
            What is Vireo Growth’s EPS estimate?
            Vireo Growth’s EPS estimate is 0.63.
              How many shares outstanding does Vireo Growth have?
              Vireo Growth has 1,455,017,300 shares outstanding.
                What happened to Vireo Growth’s price movement after its last earnings report?
                Vireo Growth reported an EPS of -C$0.546 in its last earnings report, missing expectations of C$0.209. Following the earnings report the stock price went down -1.818%.
                  Which hedge fund is a major shareholder of Vireo Growth?
                  Currently, no hedge funds are holding shares in TSE:VREO
                  What is the TipRanks Smart Score and how is it calculated?
                  Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                    Vireo Growth Stock Smart Score

                    1
                    Underperform
                    1
                    2
                    3
                    4
                    5
                    6
                    7
                    8
                    9
                    10

                    Technicals

                    SMA
                    Positive
                    20 days / 200 days
                    Momentum
                    1.63%
                    12-Months-Change

                    Fundamentals

                    Return on Equity
                    -47.54%
                    Trailing 12-Months
                    Asset Growth
                    235.25%
                    Trailing 12-Months

                    Company Description

                    Vireo Growth

                    Vireo Health International, Inc. is a holding company, which engages in the cultivation, production, and sale of medical cannabis. Its products include medical marijuana extracts in the form of oils, vaporizers, and capsules. The company was founded on November 23, 2004 and is headquartered in Minneapolis, MN.

                    Vireo Growth (VREO) Earnings & Revenues

                    VREO Company Deck

                    VREO Earnings Call

                    Q1 2026
                    0:00 / 0:00
                    Earnings Call Sentiment|Positive
                    The call emphasized transformative M&A that materially increased reported revenue and scale (GAAP revenue +333% YoY; pro forma revenue $210.2M), improved profitability (adjusted EBITDA growth and margin expansion), and a strong cash position (~$137.8M). Strategic partnerships (Glass House, FLUENT) and leadership positions in key states were highlighted as durable positives. Key risks discussed include integration execution across many acquisitions (Florida as a major near-term test), modest organic pro forma growth (+5% YoY), GAAP non-cash adjustments affecting comparability, localized operational volatility (Minnesota), regulatory/CapEx restraint evidenced by the Texas license sale, and a high share count. On balance, the financial improvements, scale and cash position outweigh the integration and regulatory risks presented on the call.View all TSE:VREO earnings summaries
                    Similar Stocks
                    Company
                    Price & Change
                    Follow
                    NeutriSci International
                    ZYUS Life Sciences
                    Luff Enterprises
                    Hash Corporation

                    Options Prices

                    Currently, No data available
                    ---
                    Popular Stocks